Translational oncogenomics最新文献

英文中文

Index 指数

Translational oncogenomics

Pub Date : 2019-01-01 DOI: 10.1016/b978-0-12-811785-9.00061-2

引用次数: 0

Bone Metastases from Solid Tumors 实体瘤的骨转移

Translational oncogenomics

Pub Date : 2019-01-01 DOI: 10.1016/B978-0-12-811785-9.00010-7

F. Silvestris, S. D’Oronzo, D. Lovero, R. Palmirotta, F. Dammacco

引用次数: 2

Translational oncogenomics

Pub Date : 2019-01-01 DOI: 10.1016/b978-0-12-811785-9.00048-x

引用次数: 0

Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors 酪氨酸激酶抑制剂治疗转移性结直肠癌的循环DNA和蛋白质生物标志物

Translational oncogenomics

Pub Date : 2019-01-01 DOI: 10.1016/B978-0-12-811785-9.00019-3

K. Søreide

引用次数: 2

From the Double Helix to Oncogenomics and Precision Cancer Medicine 从双螺旋到肿瘤基因组学和精准癌症医学

Translational oncogenomics

Pub Date : 2019-01-01 DOI: 10.1016/b978-0-12-811785-9.00001-6

F. Dammacco, F. Silvestris

引用次数: 0

TKIs in Renal Cell Carcinoma 肾细胞癌中的TKIs

Translational oncogenomics

Pub Date : 2018-11-09 DOI: 10.1016/B978-0-12-811785-9.00039-9

J. Schoon, S. Wood, Janet E Brown

引用次数: 2

Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer PARP抑制剂治疗brca缺陷上皮性卵巢癌的研究进展

Translational oncogenomics

Pub Date : 2018-11-05 DOI: 10.1016/B978-0-12-811785-9.00036-3

E. Parkes, N. Mccabe, R. Kennedy

引用次数: 0

ARID1A Expression is Down-Regulated by Oxidative Stress in Endometriosis and Endometriosis-Associated Ovarian Cancer. 子宫内膜异位症和子宫内膜异位症相关卵巢癌中的氧化应激会下调 ARID1A 的表达

Translational oncogenomics

Pub Date : 2017-02-24 eCollection Date: 2017-01-01 DOI: 10.1177/1177272716689818

Hariyono Winarto, Marselina Irasonia Tan, Mohamad Sadikin, Septelia Inawati Wanandi

Oxidative stress is considered an important factor in the development of endometriosis, including its malignant transformation. Previous studies have found that AT-rich interactive domain 1A (ARID1A), a tumor suppressor gene, is frequently mutated and inactivated in endometriosis-associated ovarian cancer (EAOC), and such a change in this gene is considered an early event in malignant transformation. We observed oxidative stress status by measuring the activity of the antioxidant enzyme manganese superoxide dismutase (MnSOD), malondialdehyde (MDA), and ARID1A gene expression in tissue samples from patients with endometriosis, EAOC, or non-endometriosis-associated ovarian cancer (non-EAOC). We also induced oxidative stress in the cultured cells from patients with primary endometriosis by adding H₂O₂ and tested for any alteration of ARID1A gene expression based on different H₂O₂ concentrations. The results showed that MnSOD activity in endometriosis and EAOC was lower than in non-EAOC, but MDA levels were higher. This study also showed that oxidative stress reduced ARID1A gene expression.

氧化应激被认为是子宫内膜异位症（包括其恶性转化）发病的一个重要因素。先前的研究发现，子宫内膜异位症相关卵巢癌（EAOC）中的肿瘤抑制基因富AT交互结构域1A（ARID1A）经常发生突变和失活，而该基因的这种变化被认为是恶性转化的早期事件。我们通过测量抗氧化酶锰超氧化物歧化酶（MnSOD）的活性、丙二醛（MDA）以及子宫内膜异位症、EAOC 或非子宫内膜异位症相关性卵巢癌（非 EAOC）患者组织样本中 ARID1A 基因的表达来观察氧化应激状态。我们还在原发性子宫内膜异位症患者的培养细胞中加入 H2O2 诱导氧化应激，并根据不同的 H2O2 浓度检测 ARID1A 基因表达的变化。结果显示，子宫内膜异位症和 EAOC 中的 MnSOD 活性低于非 EAOC，但 MDA 水平较高。这项研究还表明，氧化应激降低了 ARID1A 基因的表达。

{"title":"ARID1A Expression is Down-Regulated by Oxidative Stress in Endometriosis and Endometriosis-Associated Ovarian Cancer.","authors":"Hariyono Winarto, Marselina Irasonia Tan, Mohamad Sadikin, Septelia Inawati Wanandi","doi":"10.1177/1177272716689818","DOIUrl":"10.1177/1177272716689818","url":null,"abstract":"Oxidative stress is considered an important factor in the development of endometriosis, including its malignant transformation. Previous studies have found that AT-rich interactive domain 1A (ARID1A), a tumor suppressor gene, is frequently mutated and inactivated in endometriosis-associated ovarian cancer (EAOC), and such a change in this gene is considered an early event in malignant transformation. We observed oxidative stress status by measuring the activity of the antioxidant enzyme manganese superoxide dismutase (MnSOD), malondialdehyde (MDA), and ARID1A gene expression in tissue samples from patients with endometriosis, EAOC, or non-endometriosis-associated ovarian cancer (non-EAOC). We also induced oxidative stress in the cultured cells from patients with primary endometriosis by adding H2O2 and tested for any alteration of ARID1A gene expression based on different H2O2 concentrations. The results showed that MnSOD activity in endometriosis and EAOC was lower than in non-EAOC, but MDA levels were higher. This study also showed that oxidative stress reduced ARID1A gene expression.","PeriodicalId":88783,"journal":{"name":"Translational oncogenomics","volume":"9 ","pages":"1177272716689818"},"PeriodicalIF":0.0,"publicationDate":"2017-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/a6/10.1177_1177272716689818.PMC5398326.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34966268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. 基因组图谱在晚期乳腺癌中的作用:Janus的两面。

Translational oncogenomics

Pub Date : 2016-08-14 eCollection Date: 2016-01-01 DOI: 10.4137/TOG.S39410

Yesim Eralp

Recent advances in genomic technology have led to considerable improvement in our understanding of the molecular basis that underpins breast cancer biology. Through the use of comprehensive whole genome genomic profiling by next-generation sequencing, an unprecedented bulk of data on driver mutations, key genomic rearrangements, and mechanisms on tumor evolution has been generated. These developments have marked the beginning of a new era in oncology called "personalized or precision medicine." Elucidation of biologic mechanisms that underpin carcinogenetic potential and metastatic behavior has led to an inevitable explosion in the development of effective targeted agents, many of which have gained approval over the past decade. Despite energetic efforts and the enormous support gained within the oncology community, there are many obstacles in the clinical implementation of precision medicine. Other than the well-known biologic markers, such as ER and Her-2/neu, no proven predictive marker exists to determine the responsiveness to a certain biologic agent. One of the major issues in this regard is teasing driver mutations among the background noise within the bulk of coexisting passenger mutations. Improving bioinformatics tools through electronic models, enhanced by improved insight into pathway dependency may be the step forward to overcome this problem. Next, is the puzzle on spatial and temporal tumoral heterogeneity, which remains to be solved by ultra-deep sequencing and optimizing liquid biopsy techniques. Finally, there are multiple logistical and financial issues that have to be meticulously tackled in order to optimize the use of "precision medicine" in the real-life setting.

基因组技术的最新进展使我们对支持乳腺癌生物学的分子基础的理解有了相当大的提高。通过下一代测序技术的全面全基因组图谱分析，产生了前所未有的大量关于驱动突变、关键基因组重排和肿瘤进化机制的数据。这些发展标志着肿瘤学一个被称为“个性化或精准医疗”的新时代的开始。对支持致癌潜能和转移行为的生物学机制的阐明导致了有效靶向药物开发的不可避免的爆炸式增长，其中许多药物在过去十年中获得了批准。尽管肿瘤学界做出了积极的努力并获得了巨大的支持，但在临床实施精准医学方面仍存在许多障碍。除了众所周知的生物标志物，如ER和Her-2/neu，还没有被证实的预测标志物来确定对某种生物制剂的反应性。这方面的主要问题之一是在大量共存的乘客突变的背景噪声中戏弄驾驶员突变。通过电子模型改进生物信息学工具，通过改进对途径依赖性的洞察力来增强，可能是克服这一问题的一步。其次，肿瘤的时空异质性有待超深度测序和优化液体活检技术来解决。最后，为了优化“精准医疗”在现实生活中的应用，还有许多后勤和财务问题需要精心解决。

{"title":"The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.","authors":"Yesim Eralp","doi":"10.4137/TOG.S39410","DOIUrl":"https://doi.org/10.4137/TOG.S39410","url":null,"abstract":"Recent advances in genomic technology have led to considerable improvement in our understanding of the molecular basis that underpins breast cancer biology. Through the use of comprehensive whole genome genomic profiling by next-generation sequencing, an unprecedented bulk of data on driver mutations, key genomic rearrangements, and mechanisms on tumor evolution has been generated. These developments have marked the beginning of a new era in oncology called \"personalized or precision medicine.\" Elucidation of biologic mechanisms that underpin carcinogenetic potential and metastatic behavior has led to an inevitable explosion in the development of effective targeted agents, many of which have gained approval over the past decade. Despite energetic efforts and the enormous support gained within the oncology community, there are many obstacles in the clinical implementation of precision medicine. Other than the well-known biologic markers, such as ER and Her-2/neu, no proven predictive marker exists to determine the responsiveness to a certain biologic agent. One of the major issues in this regard is teasing driver mutations among the background noise within the bulk of coexisting passenger mutations. Improving bioinformatics tools through electronic models, enhanced by improved insight into pathway dependency may be the step forward to overcome this problem. Next, is the puzzle on spatial and temporal tumoral heterogeneity, which remains to be solved by ultra-deep sequencing and optimizing liquid biopsy techniques. Finally, there are multiple logistical and financial issues that have to be meticulously tackled in order to optimize the use of \"precision medicine\" in the real-life setting. ","PeriodicalId":88783,"journal":{"name":"Translational oncogenomics","volume":"8 Suppl 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2016-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34324496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics PI3K通路治疗药物的药效学生物标志物开发

Translational oncogenomics

Pub Date : 2016-02-21 DOI: 10.4137/tog.s30529

D. Josephs, D. Sarker

The phosphatidylinositol 3-kinase (PI3K) signaling pathway is integral to many essential cell processes, including cell growth, differentiation, proliferation, motility, and metabolism. Somatic mutations and genetic amplifications that result in activation of the pathway are frequently detected in cancer. This has led to the development of rationally designed therapeutics targeting key members of the pathway. Critical to the successful development of these drugs are pharmacodynamic biomarkers that aim to define the degree of target and pathway inhibition. In this review, we discuss the pharmacodynamic biomarkers that have been utilized in early-phase clinical trials of PI3K pathway inhibitors. We focus on the challenges related to development and interpretation of these assays, their optimal integration with pharmacokinetic and predictive biomarkers, and future strategies to ensure successful development of PI3K pathway inhibitors within a personalized medicine paradigm for cancer.

磷脂酰肌醇3-激酶(PI3K)信号通路是许多基本细胞过程的组成部分，包括细胞生长、分化、增殖、运动和代谢。导致该通路激活的体细胞突变和基因扩增在癌症中经常被检测到。这导致了针对该通路关键成员的合理设计治疗方法的发展。这些药物成功开发的关键是药效学生物标志物，旨在确定靶点和途径抑制的程度。在这篇综述中，我们讨论了在PI3K途径抑制剂的早期临床试验中使用的药效学生物标志物。我们将重点关注与这些检测的开发和解释相关的挑战，它们与药代动力学和预测性生物标志物的最佳整合，以及确保在癌症个性化医学范式中成功开发PI3K途径抑制剂的未来策略。

引用次数: 35

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Translational oncogenomics

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀